According to a recent study, prostate cancer patients receiving care at hospitals that are part of a special drug pricing program were more likely to stick to their prescription drug therapy than patients at other hospitals. The federal program requires the pharmaceutical industry to provide a discount on the cost of drugs to participating hospitals and other healthcare sites that serve a disproportionate number of Medicare and Medicaid patients.
